Related Experiment Video
Updated: Jun 22, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Structural and Functional Alterations Caused by Aureobasidin A in Clinical Resistant Strains of Candida spp
Rodrigo Rollin-Pinheiro1, Daniel Clemente de Moraes2, Brayan Bayona-Pacheco2,3
1Laboratório de Química Biológica de Microrganismos, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.
Abstract:
Candida species are one of the most concerning causative agents of fungal infections in humans. The treatment of invasive Candida infections is based on the use of fluconazole, but the emergence of resistant isolates has been an increasing concern which has led to the study of alternative drugs with antifungal activity. Sphingolipids have been considered a promising target due to their roles in fungal growth and virulence. Inhibitors of the sphingolipid biosynthetic pathway have been described to display antifungal properties, such as myriocin and aureobasidin A, which are active against resistant Candida isolates. In the present study, aureobasidin A did not display antibiofilm activity nor synergism with amphotericin B, but its combination with fluconazole was effective against Candida biofilms and protected the host in an in vivo infection model. Alterations in treated cells revealed increased oxidative stress, reduced mitochondrial membrane potential and chitin content, as well as altered morphology, enhanced DNA leakage and a greater susceptibility to sodium dodecyl sulphate (SDS). In addition, it seems to inhibit the efflux pump CaCdr2p. All these data contribute to elucidating the role of aureobasidin A on fungal cells, especially evidencing its promising use in clinical resistant isolates of Candida species.
Insights
Aureobasidin A shows promise in combating resistant Candida fungal infections. When combined with fluconazole, it effectively targets Candida biofilms and protects against infection in animal models.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections caused by Candida species are a significant global health concern.
- Fluconazole resistance in Candida isolates necessitates the exploration of alternative antifungal agents.
- Sphingolipid biosynthesis is a validated target for antifungal drug development.
Purpose of the Study:
- To investigate the efficacy of aureobasidin A, a sphingolipid biosynthesis inhibitor, against Candida biofilms and invasive infections.
- To evaluate the synergistic potential of aureobasidin A in combination with existing antifungal drugs.
- To elucidate the cellular mechanisms underlying aureobasidin A's antifungal activity.
Main Methods:
- Antifungal susceptibility testing against Candida biofilms.
- In vivo efficacy studies in a murine infection model.
- Analysis of cellular damage markers including oxidative stress, membrane potential, and DNA leakage.
- Investigation of efflux pump inhibition and cell wall integrity.
Main Results:
- Aureobasidin A alone lacked antibiofilm activity and did not synergize with amphotericin B.
- The combination of aureobasidin A and fluconazole demonstrated significant antibiofilm efficacy and in vivo protection.
- Cellular analysis revealed increased oxidative stress, reduced mitochondrial potential, and impaired cell wall integrity in treated Candida.
- Aureobasidin A appeared to inhibit the CaCdr2p efflux pump and increase susceptibility to SDS.
Conclusions:
- Aureobasidin A, particularly in combination with fluconazole, represents a promising therapeutic strategy against fluconazole-resistant Candida biofilms and infections.
- The drug induces significant cellular stress and compromises cell integrity in Candida species.
- Further research into aureobasidin A holds potential for clinical applications against challenging Candida infections.
More Related Videos
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Development of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Candidiasis
Antifungal Agents
Clinical Significance of Antibiotic Resistance

